Plasma homocysteine comes under both genetic and nutritional control. B vitamins and particularly folate are important factors in homocysteine metabolism. We have obtained reference intervals for total plasma homocysteine and plasma folate. We have also determined the in¯uence of methylenetetrahydrofolate reductase (MTHFR) genotype on plasma homocysteine concentrations in healthy individuals.
Normal metabolic pathways for homocysteine are dependent upon adequate intake of the B group vitamins: folate, vitamin B 12 , ribo¯avin and pyridoxine. Homocysteine is a common substrate for both methylation and transsulphuration pathways. The fate of homocysteine includes remethylation to methionine or conversion to cystathionine. Excess homocysteine is removed from the cell.
Methionine synthase (EC 2.1.1.13) and the cofactor methylcyanocobalamin catalyse the remethylation of homocysteine. Methylcobalamin is generated from the methylation of cob(I)alamin by 5-methyltetrahydrofolate, which is synthesized from 5,10-methylenetetrahydrofolate by methylenetetrahydrofolate reductase (MTHFR; EC 1.5. 1.20) . Pyridoxine is required as a cofactor in the conversion of homocysteine to cystathionine in the transsulphuration pathway and in the synthesis of 5, 10-methylenetetrahydrofolate. Inadequate dietary folate is the primary cause of hyperhomocysteinaemia in otherwise healthy individuals, as de®ciencies of cob(I)alamin and pyridoxine occur with lower frequency. 1±3 The form of MTHFR that is inherited has an in¯uence on folate requirements. A common mutation of MTHFR (677C?T) results in a thermolabile variant with reduced catalytic activity. 4, 5 This polymorphism is common in Caucasians. 5±7 Individuals who are homozygous for the 677T allele have a reduced ability to convert 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the primary form of plasma folate. 4, 5 Consequently, there is less folate available for the methylation of cob(I)alamin, and mild hyperhomocysteinaemia can occur when folate intake is reduced. 6, 7 Individuals with the 677TT genotype are reported to have higher mean homocysteine and lower plasma folate values than individuals possessing a 677C allele. 8 Increased homocysteine concentration in relation to folate concentration could indicate a relative metabolic de®ciency in the handling of folate.
When establishing a reference interval for homocysteine, factors such as folate status and common genetic mutations that can in¯uence homocysteine concentration in plasma should be considered. Likewise, plasma folate reference intervals should account for the need for increased folate intake in individuals with an MTHFR 677TT genotype; otherwise a signi®cant proportion of individuals may have their need for increased folate intake overlooked. We have measured plasma homocysteine and folate levels in 116 healthy volunteers. Reference intervals were obtained from the central 95% surrounding the mean values of the data. MTHFR 677 allele genotyping and folate/ homocysteine ratios were used to determine the lower reference limit for folate in this group.
METHODS AND MATERIALS
All procedures were perfomed in accordance with the regulations of the institutional review board of the Ottawa Hospital-Civic Campus. One hundred and sixteen volunteer subjects were recruited from staff of the Ottawa Hospital over a 2-month period. Patients were not recruited. All individuals were asked to refrain from participation if they were aware of pre-existing major illness or were using prescription or over-the-counter medications. Volunteers were selected to meet pre-determined quotas of males and females in various adult age categories. We included three women taking oral contraceptives and one woman using oestrogen replacement therapy as participants in order to increase the number of women volunteers in the study. We did not specify that the volunteers should be fasting prior to collection of specimens. All specimens were drawn in the daytime. At the time of collection, participants were asked whether they were taking vitamin supplements, and if so, which type.
Specimens for homocysteine and plasma folate were drawn into tubes containing EDTA. The tubes were placed on ice and centrifuged at 4 Ê C within 30 min from the time of collection.
Immediately after centrifugation, the plasma was separated from the cells and aliquots were frozen at 3 20 Ê C until analysed. Total homocysteine (oxidized and reduced) was measured using the Abbott IMx TM (Mississauga ON, Canada)¯uorescence polarization immunoassay (FPIA). Plasma folate was measured using the Abbott AxSYM TM analyser microparticle enzyme immunoassay (MEIA).
Leucocyte buffy coats from the EDTA tubes were treated with the Wizard TM genomic DNA kit (Promega, Madison WI, USA) to isolate DNA. The MTHFR genotyping assay was performed as described previously. 9 Separate EDTA tubes were collected for complete blood counts, including automated differentials, using an Abbott Cell-DYN TM haematology analyser. Volunteers were screened for hepatic and renal dysfunction by measuring sodium, potassium, chloride, bicarbonate, glucose, urea, creatinine, aspartate aminotransferase, alanine aminotransferase, g-glutamyltransferase, alkaline phosphatase, bilirubin, albumin and total protein on the Boehringer-Mannheim/ Hitachi 917 analyser (Roche, Laval PQ, Canada) using Boehringer-Mannheim/Roche reagents.
RESULTS
Of the 116 volunteers, none was excluded on the basis of abnormal chemistry or haematology results. One man admitted to coronary artery disease when he was informed his homocysteine was 18 mmol/L, and his data were excluded. Fifty-three per cent of men and 66% of women were taking a multivitamin supplement.
Least-squares linear regression analysis for the plasma homocysteine and folate relationship showed a weak negative correlation (Fig. 1 ). The regression line was folate=3 0´63 (homocysteine)+29´8, r=0´21. The mean homocysteine and folate data separated into various groups are presented in Table 1 . Log-transformed data, mean and standard deviation (SD) values were similar to the non-transformed values, even though the non-transformed data were skewed (skewness=1´13). Non-transformed data were used to establish the reference intervals for both homocysteine and folate. Figures 2 and 3 are frequency distribution plots for homocysteine and folate, respectively. Nonparametric data are also presented in Table 1 .
Male homocysteine values were signi®cantly higher than the female values (P< 0´0001). Differences in homocysteine or folate values, sorted for age by decades, were not signi®cant in any of the datasets (P> 0´05; data not shown).
This may be due to the limited number of individuals within each decade. Volunteers were selected in part by age to ensure a good representation of the adult population. Homocysteine values for men did not differ signi®cantly when grouped by vitamin supplementation (P> 0´05). Homocysteine values for women were signi®cantly different when grouped by vitamin use (P< 0´05).
Folate values did not show statistically signi®cant differences based on sex (P> 0´05). Folate values were on average approximately 4 nmol/L higher in the vitamin user groups than the non-vitamin user goups (P< 0´05). Mean and reference folate values were very similar in both the log-transformed and non-transformed datasets. Non-transformed data were used in the calculations.
The homocysteine mean and SD data, sorted by MTHFR 677C?T genotype, are presented in Table 2 . The MTHFR 677T allele frequency in our volunteers was 0´38. Of this sample, 12´9% were homozygous for the 677T mutation. This is similar to other values we have reported for patients with venous thrombosis. 9 The mean plasma homocysteine for both sexes' 677TT group was higher than the mean values observed in the 677CC groups (P=0´04). When the data were split on the basis of both sex and MTHFR 677C?T genotype, the groups became too small for statistically signi®cant conclusions to be made. No signi®cant differences in homocysteine values were observed between individuals possessing one or two C alleles at the 677 locus (P> 0´05). There were no statistically signi®cant differences between the mean folate values of the 677CC (wild-type) and 677TT groups (P> 0´05).
Total folate/homocysteine ratios are also presented in Table 2 . The mean folate/homocysteine ratios were lower in the 677TT group than in the other groups; however, the differences were not statistically signi®cant (P=0´07). The folate/homocysteine ratios in the 677TT group were lower by 16´7, 20´2 and 7´6% each for the combined sexes, male and female groups respectively, when compared with the 677CC groups. We obtained adjusted lower reference limits for folate using these values as correction factors:
[(mean folate concentration3 2 SD)2 (677CC folate/homocysteine ratio/677TT folate/homocysteine ratio)]. Likewise adjusted mean and upper reference interval limits were obtained.
Adjusted plasma folate lower reference limit values of 14´8, 13´8 and 15´1 nmol/L were calculated for the combined sexes, total male and total female groups ( Table 3 ). These lower reference limit values compensate for the differences in the concentration of homocysteine per unit value of folate observed in individuals who are homozygous for the MTHFR 677TT allele.
DISCUSSION
In this study we enrolled volunteers for random homocysteine measurements. We decided to study non-fasting individuals since many of our requests for homocysteine are on non-fasting patients who visit clinics throughout the day. Consensus has not been reached concerning the utility of fasting, postprandial or postmethionine-load homocysteine measurement. Moreover, one study has shown that more than 40% of hyperhomocysteinaemicindividuals may be missed if only fasting homocysteine is measured, 10 and another has shown that postprandial homocysteine levels are apparently not different from fasting levels. 11 We wished to see if our random homocysteine measurements were either interchangeable or substantially different from reported fasting values. Our upper limit for homocysteine is within the low-risk values described by others 12, 13 and could possibly serve as a target value considering that our study group appears to be adequately supplemented with folate. Large population studies have shown that homocysteine and risk for vascular disease follows a dose-related gradient and is related to other pre-existing risk factors. 12±14 Our plasma homocysteine values are below those cited for increased risk of vascular disease. Furthermore, our random homocysteine measurements are similar to values obtained on fasting individuals. Considering the daily requirement for methionine and cysteine is only 14 mg/ kg in total, 15 a typical 75 kg individual would then require 1050 mg of cysteine and methionine per day or 350 mg/meal, whereas a methionine-loading test uses a 3000-mg bolus of methionine. 11 Apparently, the methylation and trans-sulphuration pathway metabolic reserve is capable of handling the methionine load delivered in a meal, but not the bolus of methionine given in a methionine-loading test.
Homocysteine reference intervals were found to vary signi®cantly between sexes. This may re¯ect differences in the expression of the metabolic enzymes in folate metabolism, as well as metabolic differences in methylation and trans-sulphuration pathways. The difference in male and female homocysteine values does not appear to be related to differences in circulating folate concentrations ( Table 1 ). The higher concentration of homocysteine in men may re¯ect the increased demand for regeneration of the labile methyl pool in order to synthesize creatine. 16 Metabolic studies have shown that, in men, each homocysteine molecule is converted to methionine on average 1´9 times, whereas in women the recycling rate is 1´5 times for each molecule. 16 The inverse relationship between homocysteine and B vitamins, folate, vitamin B 12 and pyridoxine has been known for many years. 17 The more subtle genetic±environmental aspects of this relationship are only now starting to be understood. MTHFR appears to be a key regulatory enzyme for maintaining the cellular balance of 5-methyltetrahydrofolate and 5,10methylenetetrahydrofolate.
Plasma folate measurement has long been thought not to be the preferred analyte for the assessment of folate stores. Erythrocyte folate measurement is useful for this purpose. Mature erythrocytes do not absorb signi®cant quantities of folate; therefore the measurement of erythrocyte folate re¯ects a time-weighted average of intracellular folate status related to the life of the erythrocyte. Plasma folate does, however, correlate with homocysteine concentration in health and disease 18, 19 and is a dynamic measure of folate status that re¯ects hepatic regulated distribution of folate. 20, 21 We chose to measure folate in plasma for these reasons. We observed only a weak correlation between homocysteine and folate in our population. This is probably due to the limited ability for folate intake to in¯uence plasma homocysteine. There appears to be a ceiling to the effect of folate on homocysteine concentration. This upper concentration of folate at which there is no further reduction of plasma homocysteine is probably constrained within the folate values observed within our study.
Plasma folate measurements are thought to undergo signi®cant¯uctuations due to diet. The extent of in¯uence of postprandial folate absorption on plasma folate concentration is not clear for several reasons. In healthy individuals with normal dietary intake of folate, most of the circulating folate is 5-methyltetrahydrofolate that arises from the hepatic and gastric mucosal conversion of dietary folate compounds by MTHFR. 20 Thus, it appears that the enzyme MTHFR, in particular hepatic MTHFR, has a role in the distribution of folate in the body. The liver secretes 5-methyltetrahydrofolate into bile, which is subsequently reabsorbed from the bowel and distributed into the systemic circulation. 21 Moreover, absorbed 5-methyltetrahydrofolate undergoes biphasic elimination in rats. 22 The a-phase half-life is approximately 23 min, and the b-phase half-life is 8´5 h. Additionally, bile transport and gastrointestinal pH in¯uence plasma concentrations of folate. 22, 23 Disruption of bile¯ow causes a rapid decline in plasma folate concentrations. 24, 25 Bile drainage and enterohepatic circulation have been shown to be the primary contributors of plasma folate. Concentrations of plasma folate fall to 30% of control values within 4±6 h of bilē ow disruption, even in the presence of normal dietary intake. 25 The liver also demonstrates differential uptake of the various forms of folate. 25 When reabsorbed from bile, 5-methyltetrahydrofolate exhibits less hepatic uptake than demethylated species. 25 It is thought that this differential hepatic uptake facilitates the selective recycling of demethylated folate returning from extrahepatic sources. The quantity of demethylated folate returned to the liver is signi®cant. 25 It is estimated that one-third of circulating folate is derived from tissues and returns to the liver for remethylation. 25 Therefore, the primary circulating forms of folate are from both hepatic pools and extrahepatic tissue. 25 Dietary in¯uence on plasma folate is most likely a minor in¯uence in relation to hepatic regulation. Thus, it appears that hepatic biliary secretion and enterohepatic recirculation of 5-methyltetrahydrofolate are crucial for the maintenance of plasma folate and subsequent distribution to tissues. 21, 25 Taken together these observations validate the use of random plasma samples when assessing folate in relation to homocysteine. These observations also provide evidence that hepatic MTHFR controls a signi®cant portion of circulating folate.
The common polymorphism in MTHFR suggests that there has been selective evolutionary pressure, possibly related to folate conservation, and perhaps during foetal development. This is supported in part by the observation that MTHFR de®ciency is an associated risk factor for neural tube defects. 26 The T allele is well established in the genome, most likely because adequate folate stabilizes MTHFR 4 and restores normal methylation status.
Individuals with the MTHFR 677TT genotype phenotypically have reduced MTHFR catalytic activity. This is apparent from the folate/homocysteine ratios derived for each genotype ( Table 2) . A low ratio indicates an increased concentration of homocysteine in relation to a given concentration of the methyl carbon donor, 5-methyltetrahydrofolate. Folate de®ciency will cause hyperhomocysteinaemia regardless of MTHFR genotype. However, individuals with the 677TT genotype require a greater folate intake to maintain low homocysteine levels because the thermolabile form of the enzyme has reduced catalytic activity. Our adjusted lower folate cut-off of 14´8 nmol/L, which was derived from the differences in folate/ homocysteine ratios for 677CC and 677TT genotypes for the combined male and female groups, takes into consideration the greater folate requirements of individuals homozygous for the MTHFR 677T allele. Brouwer et al. 27 have suggested a lower folate reference limit of 10 nmol/L based on their ®ndings that no further reduction in homocysteine was observed at this cut-off in a Dutch population. This con¯icts with the ®ndings of others that suggest that a plasma folate of 15´4 nmol/L is required to eliminate the hyperhomocysteinaemic effect of the thermolabile variant of MTHFR. 28 Our data suggest that random homocysteine values are similar to fasting values in a normal population and do not re¯ect the values that would be encountered with methionine loading. Although the differences in mean homocysteine values between our study and Brouwer's may be related to methodological differences in homocysteine measurement, they may also relate to differences in folate status in our populations. The mean folate values at the start of Brouwer's study were less than half of our mean folate values; thus it is likely that the long-term folate intake of our subjects is signi®cantly greater. Brouwer et al. 27 noted that 31% of their volunteers had initial plasma folate concentrations below 10 nmol/L, whereas only 3´4% of our subjects had folate concentrations less than 15 nmol/L and none had values below 10 nmol/L.
CONCLUSION
We have measured homocysteine and folate in 116 volunteers. Based on MTHFR genotype and the folate/homocysteine ratio, we have derived a lower non-fasting reference limit for folate that should be adequate to prevent de®ciency with respect to homocysteine remethylation. We have also determined that the non-fasting plasma homocysteine upper reference limit in our population is similar to the low-risk values observed in other large studies. 13 This reference interval is similar to other fasting homocysteine reference intervals, indicating that short-term dietary in¯uences on homocysteine are probably minor. We have also determined that the MTHFR 677TT genotype affects plasma homocysteine levels even when folate concentrations are optimal. This genetic effect is also re¯ected in the folate/homocysteine ratios obtained in our study.
